Bernstein said Novo Nordisk’s (NVO) recently released SOUL study results for Rybelsus in the reduction of major ...
Zacks.com on MSN7h
NVO's Rybelsus Meets Primary Goal in MACE Study for Diabetes PatientsNovo Nordisk NVO announced positive top-line data from a late-stage cardiovascular outcomes study that evaluated its oral ...
As Novo Nordisk’s injectable diabetes-obesity duo Ozempic and Wegovy grab all the limelight, an oral version of the ...
According to new data from the SOUL trial Oral semaglutide reduced MACE by 14% in Type 2 Diabetes patients. Novo Nordisk will ...
In Novo Nordisk’s randomized clinical trial, semaglutide reduced the risk for major adverse cardiovascular events by 14% ...
SOUL Trial Results Position Rybelsus as a Game-Changer in Diabetes and Cardiovascular Care, Poised for Expanded U.S. and E.U.
Novo Nordisk's SOUL trial reveals a 14% reduction in major cardiovascular events with oral semaglutide in patients with type ...
Novo Nordisk on Monday reported the oral version of its drug semaglutide reduced the risk of major adverse cardiovascular events in adults with type 2 diabetes by 14% in a large Phase III trial.
The medicine, which Novo sells as Rybelsus, cut the risk of cardiovascular complications by 14% when added to standard therapies in people with diabetes and heart disease.
Rybelsus (semaglutide) is a prescription drug used to manage blood sugar levels in adults with type 2 diabetes. Rybelsus can cause mild to severe side effects that may include constipation and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback